Anders Olsson

Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study

Jennifer G. Robinson, J. D. Jordan, G. Molenberghs, 2016, Journal of the American Heart Association.

Characterization of a Manganese-Containing Nanoparticle as an MRI Contrast Agent

R. Petoral, E. Gianolio, S. Aime, 2019, European Journal of Inorganic Chemistry.

RE: Praluent (Alirocumab)-Induced Renal Injury

D. Waters, R. Rosenson, D. Larrey, 2017, Journal of pharmacy practice.